CS
AXSM icon

Cannell & Spears’s Axsome Therapeutics AXSM Stock Holding History

Cannell & Spears’s Portfolio AXSM Stock Details AXSM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$20.6M Hold
84,154
– – 0.37% 71
2026
Q1 		$14.2M Hold
84,154
– – 0.28% 84
2025
Q4 		$15.4M Buy
84,154
+3
+0% +$419 0.29% 84
2025
Q3 		$10.2M Hold
84,151
– – 0.19% 100
2025
Q2 		$8.78M Sell
84,151
-113
-0.1% -$12K 0.18% 103
2025
Q1 		$9.83M Buy
84,264
+2,177
+3% +$248K 0.21% 99
2024
Q4 		$6.95M Hold
82,087
– – 0.14% 114
2024
Q3 		$7.38M Sell
82,087
-5
-0% -$436 0.15% 114
2024
Q2 		$6.61M Sell
82,092
-638
-0.8% -$47.2K 0.14% 112
2024
Q1 		$6.6M Buy
+82,730
New +$6.94M 0.14% 117

Other funds holding AXSM

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Cannell & Spears's AXSM Position: Q2 2026 in Review

Cannell & Spears held its Axsome Therapeutics (AXSM) position steady in Q2 2026 at 84,154 shares worth $20.6M. The position accounts for 0.37% of the portfolio, ranked #71.

Cannell & Spears first reported a position in AXSM in Q1 2024 and has held it in 10 quarters since. 505 funds tracked by Wall St. Rank hold AXSM as of Q2 2026.

  • Cannell & Spears held 84,154 shares of Axsome Therapeutics worth $20.6M as of Q2 2026.
  • Cannell & Spears left its Axsome Therapeutics share count unchanged in Q2 2026.
  • Axsome Therapeutics made up 0.37% of Cannell & Spears's portfolio in Q2 2026, its #71 holding.
  • Cannell & Spears first reported a position in Axsome Therapeutics in Q1 2024 and has held it in 10 quarters since.
  • 505 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q2 2026.

Based on Cannell & Spears's 13F filing for Q2 2026, filed 11 Aug 2026.